Latest News for: abl1

Edit

EHA 2026 | HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML) (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 12 Jun 2026
HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR..ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML) ... It potently inhibits the phosphorylation of ABL1 and its ...
Edit

Targeting the ANGPTL4/NRP1/ABL1/RAD51 axis reverses cisplatin resistance by impairing DNA damage repair in head and ...

PNAS 26 Mar 2026
... Neuropilin1 to activate ABL1, which in turn phosphorylates and ...
Edit

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML (Form 8-K) (Terns Pharmaceuticals Inc)

Public Technologies 25 Mar 2026
Terns' lead candidate TERN-701 is an investigational oral allosteric BCR..ABL1 tyrosine ... "The first approval of a BCR..ABL1 tyrosine kinase inhibitor 25 years ago transformed the prognosis for many patients with chronic myeloid leukemia.
  • 1

Article Search

tools
×
×
×
×